GenSight Biologics
Develops innovative therapies for mitochondrial and neurodegenerative diseases.
Launch date
Employees
Market cap
$43.8m
Enterprise valuation
$62m (Public information from Sep 2024)
Share price
€0.395 SIGHT.PA
Company register number 751164757
Paris Île-de-France (HQ)
Authorizing premium user...